MAIA ▲ +3.0% - MAIA Biotechnology, Inc. $MAIA - MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial MAIA Biotechnology dosed its first U.S. patient in an ongoing Phase 2 clinical trial for non-small cell lung cancer, a milestone that signals progress in the company's development pipeline. The 3.0% gain reflects investor optimism around the expansion of this trial into the U.S. market. 16-SEP-2026 08:15 AM ET